The Langar Global HealthTech ETF (LGHT) seeks to provide exposure to global healthcare technology companies that develop innovative medical devices, digital health solutions, and biotechnology applications. This international equity ETF focuses on companies leveraging technology to transform healthcare delivery and patient outcomes worldwide.
How It Works
LGHT employs an actively managed approach to select healthcare technology companies across developed and emerging markets. The fund's portfolio managers use fundamental analysis to identify firms with strong growth potential in areas like telemedicine, medical AI, genomics, and digital therapeutics. Holdings are weighted based on conviction levels rather than market capitalization, with regular rebalancing to capture emerging opportunities in the rapidly evolving healthtech sector.
Key Features
- Targets the intersection of healthcare and technology, capturing growth from digital transformation in medical industries globally
- Active management allows for nimble positioning in emerging healthtech subsectors like AI diagnostics and personalized medicine
- Zero expense ratio structure makes it cost-competitive for accessing specialized international healthcare technology exposure
Risks
- This ETF can lose significant value if healthcare technology stocks fall out of favor or face regulatory setbacks, potentially declining 40-50% during sector rotations
- International exposure creates currency risk where strengthening U.S. dollar reduces returns from foreign holdings, impacting performance by 5-15% annually
- Small fund size with zero AUM creates liquidity concerns and potential closure risk if the ETF fails to attract sufficient investor interest
Who Should Own This
Best suited as a satellite holding (5-15% of portfolio) for growth-oriented investors with high risk tolerance and 3-7 year time horizons. Appropriate for those seeking targeted exposure to healthcare innovation trends and comfortable with sector concentration risk and international market volatility.